Shattuck Labs, Inc. (STTK): Results of Operations and Financial Condition
Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sttk_2q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism i
How this was made
The 30-second read
Why it matters
The most tradable elements are the specific Phase 1 SL-325 findings (immunogenicity rate, durable TL1A blockade, no DR3 agonism), the planned Phase 2b initiation in Q3 2026, and the strengthened balance sheet expected to fund operations into 2029.
Market read
Traders can update probability-weighted biotech success and financing risk based on new clinical readouts and explicit cash runway guidance.
What to watch
Cash runway into 2029 reduces financing pressure, but the company still faces dilution risk if Phase 2b or later trials require additional capital before results in 1H 2028.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings release covering Q2 2026 financials and SL-325/SL-846 development updates.
Ticker impact
Shattuck reported Q2 2026 results and disclosed Phase 1 SL-325 data, including 3.7% antidrug antibodies and durable TL1A blockade.
Near-term upside bias as traders price improved efficacy/safety signals and reduced financing risk into 2029.
The filing is a primary disclosure (8-K with earnings release) and includes specific clinical and balance-sheet datapoints that can shift biotech risk perception and funding expectations.
Market effects
Supports sentiment for DR3/TL1A pathway immunology peers by reinforcing target biology and dosing durability narrative.
Limited, company-specific biotech catalyst with no clear regional macro linkage.
Moderate for global IBD immunology investors tracking DR3/TL1A bispecific/monoclonal development timelines.
Counterpoint
Phase 1 immunogenicity and binding blockade do not guarantee Phase 2b endoscopic response; efficacy may disappoint despite favorable safety.
Key entities
- companyShattuck Labs, Inc.
Clinical-stage biotech developing DR3 blocking antibodies, reporting Q2 2026 results and SL-325/SL-846 updates.
- product_candidateSL-325
Lead DR3 blocking antibody; Phase 1 results highlighted favorable immunogenicity and durable TL1A blockade.
- clinical_trialRECEPTIVE-CD1
Phase 2b Crohn’s disease trial expected to initiate in Q3 2026, with primary endpoint endoscopic response at 12 weeks.
- product_candidateSL-846
Half-life extended DR3 x IL-23 receptor blocking bispecific; IND-enabling GLP tox ongoing with initial Phase 1 expected in 2027.
